The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine.

Slides:



Advertisements
Similar presentations
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Advertisements

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Volume 14, Issue 8, Pages (December 2011)
Value in Health Regional Issues
Value in Health Regional Issues
Value in Health Regional Issues
An Audit of Diabetes-Dependent Quality of Life (ADDQOL) in Older Patients with Diabetes Mellitus Type 2 in Slovenia  Eva Turk, MA, MBA, Valentina Prevolnik.
Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period  J. Liñares, C. Ardanuy, R. Pallares, A.
Value in Health Regional Issues
The Development of the Romanian Scorecard HTA System
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan  Kaoru Yamabe, MSc, Puneet K. Singhal,
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
Value in Health Regional Issues
Value in Health Regional Issues
Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs)
The Process of Privatization of Health Care Provision in Poland
Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
Value in Health Regional Issues
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Value in Health Regional Issues
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
Value in Health Regional Issues
Economic Evaluation of Bariatric Surgery in Mexico Using Discrete Event Simulation  Olivo Omar Zanela, MSc, Hermilo Arturo Cabra, MSc, Guillermo Meléndez,
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
Burden of Disease and Economic Impact of Dengue and Severe Dengue in Colombia, 2011  Carlos Castañeda-Orjuela, MD, MSc, Hernando Díaz, PhD, Nelson Alvis-Guzman,
Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Omneya Mohamed, PhD, David H. Kreling, PhD 
Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M
Value in Health Regional Issues
Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis  Cynthia Chen, PhD, Francisco Cervero Liceras, MSc, Stefan.
The Economic Impact of Cigarette Smoking on the Poor in Jordan
Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?  Fei-Li.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Children Hospitalized for Varicella: Complications and Cost Burden
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Economic Burden of Individual Suffering from Atrial Fibrillation–Related Stroke in China  Shanlian Hu, MSc, Lin Zhan, MSc, Bao Liu, MD, PhD, Yue Gao, MD,
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Incidence of Intravenous Medication Errors in a Chinese Hospital
Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan  Yoshie Onishi, MS,
The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System  Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Value in Health Regional Issues
Clinical Microbiology and Infection
Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia  Vlado Jukic, MD, PhD, Miro Jakovljevic, MD, PhD, Igor Filipcic,
Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries  Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.
A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina  Joaquín.
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
Value in Health Regional Issues
One-way sensitivity analysis.
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine as Compared with 13-Valent Pneumococcal Conjugate Vaccine in Hong Kong  Kenneth K.C. Lee, BSc (Pharm), MPhil, PhD, David Bin Chia Wu, PhD, Oleksandr Topachevskyi, BSc, Emmanuelle Delgleize, MSc, Rodrigo DeAntonio, MD, MSc  Value in Health Regional Issues  Volume 2, Issue 1, Pages 64-74 (May 2013) DOI: 10.1016/j.vhri.2013.01.012 Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 (A) Model structure. (B) Modeled age compartments and vaccine efficacy periods. AOM, acute otitis media; PCV-10, pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine. Value in Health Regional Issues 2013 2, 64-74DOI: (10.1016/j.vhri.2013.01.012) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 One-way sensitivity analysis. AOM, acute otitis media; GP, general practitioner; HKD, Hong Kong dollars; IPD, invasive pneumococcal disease; NTHi, nontypeable Haemophilus influenzae; PCV-10, pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; QALY, quality-adjusted life-year. Value in Health Regional Issues 2013 2, 64-74DOI: (10.1016/j.vhri.2013.01.012) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 One-way scenario analysis. AOM, acute otitis media; GP, general practitioner; HKD, Hong Kong dollars; IPD, invasive pneumococcal disease; PCV-10, pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; QALY, quality-adjusted life-year; VE, vaccine effectiveness. Value in Health Regional Issues 2013 2, 64-74DOI: (10.1016/j.vhri.2013.01.012) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Two-way scenario analysis. AOM, acute otitis media; GP, general practitioner; HKD, Hong Kong dollars; IPD, invasive pneumococcal disease; PCV-10, pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; QALY, quality-adjusted life-year; VE, vaccine effectiveness. Value in Health Regional Issues 2013 2, 64-74DOI: (10.1016/j.vhri.2013.01.012) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 Probabilistic sensitivity analysis PCV-10 versus PCV-13 in Hong Kong. WHO highly cost-effectiveness threshold for Hong Kong is less than GDP per capita (Hong Kong GDP per capita is HKD 266,026) [38,40]. GDP, gross domestic product; HKD, Hong Kong dollars; PCV-10, pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; QALY, quality-adjusted life-year; WHO, World Health Organization. Value in Health Regional Issues 2013 2, 64-74DOI: (10.1016/j.vhri.2013.01.012) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.